Safety of Biological Medicinal Products for Hereditary Coagulopathies: An Analysis of the Russian Pharmacovigilance Database

Safety of Biological Medicinal Products for Hereditary Coagulopathies: An Analysis of the Russian Pharmacovigilance Database

INTRODUCTION. With the expanding product range and the introduction of novel biological medicinal products for haemophilia A, haemophilia B, and von Willebrand disease in the Russian pharmaceutical market, post-marketing safety surveillance becomes especially important.AIM. This study aimed to compr...

Full description

Saved in:
Bibliographic Details
Main Authors: D. S. Fokina, O. V. Zhukova, A. L. Khokhlov
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2025-06-01
Series:Безопасность и риск фармакотерапии
Subjects:
haemophilia
von willebrand disease
emicizumab
coagulation factor viii
haemarthrosis
bleeding
adverse drug reactions
drug safety
pharmacovigilance
spontaneous reports
vigibase
Online Access:https://www.risksafety.ru/jour/article/view/477
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.risksafety.ru/jour/article/view/477

Similar Items